$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics

Medtronic CY Q4 ’24 (FY Q3 ‘25) Earnings; FDA Approves Biosimilar Novolog; Allurion Balloon + GLP-1RA; Ph2 Oral VK2735 Trial Observed

A series of cardiometabolic-related news items have been observed from Medtronic, Sanofi, Allurion Technologies, and Viking Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home